Potency of three opiate antagonists to reverse the inhibitory activity of dynorphin, enkephalins and opioid-like alkaloids on the guinea pig ileum.
To test the hypothesis that dynorphin is a K-opiate agonist acting on the myenteric plexus, the potency of two benzomorphan antagonists (Win 44, 441 and Mr 2266) to block the inhibitory action of dynorphin, enkephalins and opioid alkaloids was determined on the longitudinal muscle preparation of the guinea pig ileum. The effectiveness of these antagonists was compared to that of naloxone. Antagonistic potency was established by calculating the apparent antagonist dissociation constant, Ke, as derived from Schild plots. Win 44, 441 and Mr 2266 were about 7-8 times more potent than naloxone against dynorphin, dynorphin-(1-13) or ethylketocyclazocine. Although the Ke obtained with Win 44, 441 or Mr 2266 against dynorphin or ethylketocyclazocine were significantly lower than those of naloxone, the values obtained for these antagonists did not differ significantly in the case of each of these agonists. With respect to the antagonism of the enkephalins or normorphine, Win 44, 441 was the most potent antagonist. Its Ke value for the enkephalins was 2.5-3 times lower than those for dynorphin or ethylketocyclazocine and in comparison to naloxone, Win 44, 441 was about 5 times more potent. Although Mr 2266 was a potent antagonist of dynorphin, ethylketocyclazocine, the enkephalins or normorphine, it showed no selectivity of action. The fact that the 3 opiate antagonists evidenced similar Ke values for dynorphin and ethylketocyclazocine, but different ones for the enkephalins or normorphine supports the conclusion that dynorphin activates preferentially K- but not mu-opiate receptors in the myenteric plexus.
D000818:Animals; D001392:Azocines / Q000494:pharmacology; D001575:Benzomorphans / Q000031:analogs & derivatives / Q000494:pharmacology; D003496:Cyclazocine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D004399:Dynorphins; D004723:Endorphins / Q000037:antagonists & inhibitors*; D004745:Enkephalins / Q000037:antagonists & inhibitors*; D016314:Ethylketocyclazocine; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D009022:Morphine Derivatives / Q000037:antagonists & inhibitors; D009130:Muscle, Smooth / Q000187:drug effects*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*
D001392:Azocines; D001575:Benzomorphans; D004723:Endorphins; D004745:Enkephalins; D009022:Morphine Derivatives; D009292:Narcotic Antagonists; D009270:Naloxone; C027247:MR 2266; D016314:Ethylketocyclazocine; D004399:Dynorphins; D003496:Cyclazocine; C035969:quadazocine; C010616:normorphine